Physician profile
Eric A Weber
NPI 1376572966
$1,653.78
in general payments reported to CMS, 2019-2025
21 companies · $319 in 2025
The $319 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $780 · 2020: $124 · 2021: $63.03 · 2022: $76.25 · 2023: $115 · 2024: $177 · 2025: $319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $611.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $611.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $262.22 | 2019-2025 | |
| Novo Nordisk INC | $237.84 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $139.49 | 2019-2025 | Arexvy, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $131.36 | 2019-2025 | |
| Lilly USA, LLC | $123.04 | 2021-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.09 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $111.37 | 2019-2025 | Airsupra, Breztri |
| Abbvie INC. | $108.93 | 2019-2025 | |
| Allergan, INC. | $66.05 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $57.84 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $54.34 | 2024-2025 | Austedo Xr, Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $46.62 | 2019 | |
| Merck Sharp & Dohme LLC | $33.66 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $31.75 | 2023 | Quviviq |
| Amarin Pharma, INC. | $27.56 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.76 | 2025 | Xifaxan |
| Shire North American Group INC | $20.74 | 2019 | |
| Jazz Pharmaceuticals INC. | $19.35 | 2024 | |
| Amgen INC. | $16.76 | 2024 | Otezla, Repatha |
| Astellas Pharma US INC | $12.89 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $11.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Weber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.